Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Our ChoiceTM Discovery Platform is the foundation of our oncolytic immunotherapy development, having produced over 500 different versions of the vaccinia virus. Olvi-Vec, our lead product candidate is currently in a Phase 3 registrational clinical trial for Platinum-Resistant/Refractory Ovarian Cancer (PRROC). Olvi-Vec is also being developed in Non-Small Cell Lung Cancer (NSCLC), recurrent Small Cell Lung Cancer (SCLC), and recurrent Ovarian Cancer. We are dedicated to advancing a pipeline of next-generation oncolytic immunotherapies that deliver the full complement of tumor neo-antigens with the power to stimulate a personalized immune response for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Information about our investigational products and clinical trials can be found here. For more information, please visit https://genelux.com/ and follow us on Twitter @Genelux_Corp and Facebook @Genelux. Olvi-Vec is an investigational product candidate not yet approved by the US Food and Drug Administration.
View Top Employees from GeneluxWebsite | https://genelux.com/ |
Revenue | $5 million |
Employees | 31 (24 on RocketReach) |
Founded | 2001 |
Address | Westlake Village, California, Maryland, US |
Phone | (858) 483-0024 |
Fax | (858) 483-0026 |
Industry | Biotechnology Research, Drug Manufacturing & Research, Biopharma, Pharmaceuticals, Biotechnology, Healthcare, Health Care, Science and Engineering, Health Diagnostics |
Web Rank | 5 Million |
Keywords | Genelux Corporation, Genelux, Therapix Medical Solutions |
Competitors | DNAtrix, HARBOUR BIOMED, Neotropix, Oncolytics Biotech Inc., Soricimed Biopharma Inc. |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 5417 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 541714 Companies, NAICS Code 54171 Companies |
Looking for a particular Genelux employee's phone or email?
The Genelux annual revenue was $5 million in 2024.
Thomas Zindrick is the President, Chief Executive Officer and Chairman of Genelux.
24 people are employed at Genelux.
Genelux is based in California, Maryland.
The NAICS codes for Genelux are [5417, 541, 54, 541714, 54171].
The SIC codes for Genelux are [87, 873].